دورية أكاديمية
Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis
| العنوان: | Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis |
|---|---|
| المؤلفون: | Pollastro, Sabrina, Musters, Anne, Balzaretti, Giulia, Niewold, Ilse, van Schaik, Barbera, Hässler, Signe, Verhoef, Catharina M., Pallardy, Marc, van Kampen, Antoine, Mariette, Xavier, de Vries, Niek |
| المساهمون: | Amsterdam UMC - Amsterdam University Medical Center, University of Amsterdam Amsterdam = Universiteit van Amsterdam (UvA), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Immunologie - Immunopathologie - Immunothérapie CHU Pitié Salpêtrière (I3), CHU Charles Foix AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre d'investigation clinique Biothérapie CHU Pitié-Salpêtrière (CIC-BTi), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Inflammation, microbiome, immunosurveillance (MI2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre de recherche en Immunologie des Infections virales et des maladies auto-immunes, Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Saclay, Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Salima Hacein-Bey Abina, IMI-funded, ZonMw, ABIRISK Consortium: Natacha Szely, Aude Gleizes, Salima Hacein-Bey Abina, Christophe Richez, Martin Soubrier, Jérome Avouac, Olivier Brocq, Jérémie Sellam, Tom Huizinga, Elizabeth Jury, Jessica Manson, Claudia Mauri, Andrea Matucci |
| المصدر: | ISSN: 1478-6354 ; Arthritis Research and Therapy ; https://hal.science/hal-04615209Test ; Arthritis Research and Therapy, 2024, 26 (1), pp.70. ⟨10.1186/s13075-024-03297-7⟩. |
| بيانات النشر: | HAL CCSD BioMed Central |
| سنة النشر: | 2024 |
| المجموعة: | Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| مصطلحات موضوعية: | AIRR-seq, B cells, B-cell receptor repertoire, Rheumatoid arthritis, Rituximab, [SDV]Life Sciences [q-bio] |
| الوصف: | International audience ; Background: Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself.Methods: The B-cell receptor (BCR) repertoire was prospectively analyzed in peripheral blood samples of twenty-eight RA patients undergoing rituximab therapy. Timepoints of achieved BCR-depletion and -repopulation were defined based on the percentage of unmutated BCRs in the repertoire. The predictive value of early BCR-depletion (within one-month post-treatment) and early BCR-repopulation (within 6 months post-treatment) on clinical response was assessed.Results: We observed changes in the peripheral blood BCR repertoire after rituximab treatment, i.e., increased clonal expansion, decreased clonal diversification and increased mutation load which persisted up to 12 months after treatment, but started to revert at month 6. Early BCR depletion was not associated with early clinical response but late depleters did show early response. Patients with early repopulation with unmutated BCRs showed a significant decrease in disease activity in the interval 6 to 12 months. Development of anti-drug antibodies non-significantly correlated with more BCR repopulation.Conclusion: Our findings indicate that rather than BCR-depletion it is repopulation with unmutated BCRs, possibly from naïve B cells, which induces remission. This suggests that (pre-existing) differences in B-cell turnover between patients explain the interindividual differences in early clinical effect. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/38493208; hal-04615209; https://hal.science/hal-04615209Test; https://hal.science/hal-04615209/documentTest; https://hal.science/hal-04615209/file/s13075-024-03297-7.pdfTest; PUBMED: 38493208; PUBMEDCENTRAL: PMC10943808 |
| DOI: | 10.1186/s13075-024-03297-7 |
| الإتاحة: | https://doi.org/10.1186/s13075-024-03297-7Test https://hal.science/hal-04615209Test https://hal.science/hal-04615209/documentTest https://hal.science/hal-04615209/file/s13075-024-03297-7.pdfTest |
| حقوق: | http://creativecommons.org/licenses/byTest/ ; info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.761C9BC7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1186/s13075-024-03297-7 |
|---|